Overview

The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer

Status:
Completed
Trial end date:
2008-07-17
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effect of the study drug (GW679769) on a commonly used chemotherapy drug (docetaxel) which will be given I.V. Blood samples will be taken to see if the GW679769 alters the blood levels of the chemotherapy. The study will last about 2 weeks with a final follow-up visit 6 weeks later.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Casopitant
Docetaxel
Neurokinin-1 Receptor Antagonists